JP2025502891A - 自己免疫性脳炎のサトラリズマブによる治療 - Google Patents

自己免疫性脳炎のサトラリズマブによる治療 Download PDF

Info

Publication number
JP2025502891A
JP2025502891A JP2024543040A JP2024543040A JP2025502891A JP 2025502891 A JP2025502891 A JP 2025502891A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2025502891 A JP2025502891 A JP 2025502891A
Authority
JP
Japan
Prior art keywords
encephalitis
satralizumab
subject
nmdar
lgi1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502891A5 (https=
JPWO2023140269A5 (https=
Inventor
孝俊 小澤
広顕 井田
創 伊藤
俊介 吉田
ジリアン スミス
シアン レノン－クライムズ
ガエル クリンゲルシュミット
ビューディンゲン ハンス－クリスチャン フォン
バウマン ハンナ シルバー
ジェームズ オーヴェレル
シャルミラ ラジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025502891A publication Critical patent/JP2025502891A/ja
Publication of JP2025502891A5 publication Critical patent/JP2025502891A5/ja
Publication of JPWO2023140269A5 publication Critical patent/JPWO2023140269A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024543040A 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療 Pending JP2025502891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (3)

Publication Number Publication Date
JP2025502891A true JP2025502891A (ja) 2025-01-28
JP2025502891A5 JP2025502891A5 (https=) 2026-01-14
JPWO2023140269A5 JPWO2023140269A5 (https=) 2026-01-14

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543040A Pending JP2025502891A (ja) 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療

Country Status (11)

Country Link
US (1) US20250127891A1 (https=)
EP (1) EP4466018A4 (https=)
JP (1) JP2025502891A (https=)
KR (1) KR20240145472A (https=)
CN (1) CN118900699A (https=)
AU (1) AU2023209259A1 (https=)
CA (1) CA3243067A1 (https=)
IL (1) IL314213A (https=)
MX (1) MX2024008835A (https=)
TW (1) TW202337495A (https=)
WO (1) WO2023140269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
JPWO2020202839A1 (https=) * 2019-03-29 2020-10-08

Also Published As

Publication number Publication date
TW202337495A (zh) 2023-10-01
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
CA3243067A1 (en) 2023-07-27
CN118900699A (zh) 2024-11-05
IL314213A (en) 2024-09-01
AU2023209259A1 (en) 2024-07-18
WO2023140269A1 (en) 2023-07-27
EP4466018A1 (en) 2024-11-27
US20250127891A1 (en) 2025-04-24
KR20240145472A (ko) 2024-10-07

Similar Documents

Publication Publication Date Title
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
US20250034265A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
EP4058060B1 (en) Type i interferon inhibition in systemic lupus erythematosus
Correa-Díaz et al. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
Clardy et al. Therapeutic approach to autoimmune neurologic disorders
Yu et al. First‐in‐Human Study of BAT4406F, an ADCC‐Enhanced Fully Humanized Anti‐CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders
KR20090063215A (ko) 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
TW202233676A (zh) 使用抗ｃｄ１９抗體治療自體免疫性疾病
HK40111127A (zh) 使用萨特利珠单抗治疗自身免疫性脑炎
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
EP4370547A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
WO2020017629A1 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
Boiko et al. Contemporary algorithms for the diagnosis and treatment of multiple sclerosis based on individual assessment of patients’ status
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
KR20260033556A (ko) (r)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여함으로써 아동, 청소년 및 성인에서 지속성 또는 만성 면역 혈소판감소증을 치료하는 방법
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
HK40080317B (en) Type i interferon inhibition in systemic lupus erythematosus
HK40080317A (en) Type i interferon inhibition in systemic lupus erythematosus
Holmes et al. Drug Class Review Disease-modifying Drugs for Multiple Sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251226